Stay updated on I-SPY Trial: Personalized Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the I-SPY Trial: Personalized Breast Cancer Clinical Trial page.

Latest updates to the I-SPY Trial: Personalized Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe site revision identifier in the footer changes from v3.7.1 to v3.7.2 on the 403 Forbidden page.SummaryDifference0.2%

- Check14 days agoChange DetectedThe site footer revision changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check35 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content and navigation, blocking access to the trial details. This indicates access is blocked for the study page.SummaryDifference26%

- Check49 days agoChange DetectedA publication entry for Cemiplimab and Fianlimab with neoadjuvant chemotherapy in early-stage ERBB2-negative breast cancer (I-SPY2) was updated to include online-ahead-of-print status and the e262576 article number, replacing the previous citation.SummaryDifference0.0%

- Check56 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6, representing a minor update to the Study Details page.SummaryDifference0.0%

- Check63 days agoChange DetectedA medRxiv preprint by Magbanua et al. on circulating tumor DNA as a prognostic factor in neoadjuvant breast cancer therapy was added to the Publications list, expanding the study's biomarker references.SummaryDifference0.0%

Stay in the know with updates to I-SPY Trial: Personalized Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the I-SPY Trial: Personalized Breast Cancer Clinical Trial page.